Company / Return on Equity (ROE)
Imunon, Inc. Return on Equity (ROE) History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-122.4%
FY2023
5-year range
-122.4% / -37.2%
FY2019-FY2023
Trend
-228.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Imunon, Inc. reports negative total equity of -122.4% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-122.4% in FY2023 with a 5-year CAGR of -46.0%.
Declined from -115.4% to -122.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -6.7pp
- 5-Year Change
- -46.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 228.9% year-over-year.
- Peak return on equity (roe) was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -122.4% | -228.9% |
| FY2022 | -37.2% | +67.8% |
| FY2021 | -115.4% | +0.3% |
| FY2020 | -115.8% | -103.2% |
| FY2019 | -57.0% | +25.4% |
| FY2018 | -76.4% | -203.9% |
| FY2015 | -25.1% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026